Protocol Ledger

NCT05392192 · Phase II · COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Interventional Phase II clinical trial protocol NCT05392192 sponsored by Aldeyra Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-07 Enrollment: 51 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05392192
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)51 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05392192
Protocol FieldVerified Registry Value
NCT IdentifierNCT05392192
Consolidated Lead SponsorAldeyra Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment51 participants (ACTUAL)
Registered Start Date2022-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05392192
Hospital Research SiteLocationSite Profile
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI